In line with this hypothesis, a recent report in HCC identified an AFP-peptide (AFP-158)-specific T cell receptor (TCR) that promotes dramatic activity in in vitro and in vivo tumor models [7] and the development of AFP-targeted chimeric antigen receptor therapy is underway [8]. This evidence concerns the gene AFP and hepatocellular carcinoma.